Render Target: STATIC
Render Timestamp: 2024-10-08T09:56:05.691Z
Commit: f04ddd7fea9fb3592f59f61482fcb94610d25cbe
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

FKBP1A/FKBP12 (E8H7Y) Rabbit mAb #94838

Filter:
  • WB

    Supporting Data

    REACTIVITY H M R
    SENSITIVITY Endogenous
    MW (kDa) 12
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    Species Cross-Reactivity Key:
    • H-Human 
    • M-Mouse 
    • R-Rat 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    FKBP1A/FKBP12 (E8H7Y) Rabbit mAb recognizes endogenous levels of total FKBP1A/FKBP12 protein.

    Species Reactivity:

    Human, Mouse, Rat

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Phe49 of human FKBP1A/FKBP12 protein.

    Background

    FKBP12 (FKBP1A) is a prototypical member of the FKBP (FK506 binding protein) family of immunophilins, so named because of the ability of FKBP12 to bind to the immunosuppressive drug FK506 (tacrolimus) (1). The protein is the smallest member in the family and contains only one peptidylprolyl isomerase (PPIase) core domain (FK domain) responsible for its PPIase activity and its binding to FK506 and other compounds (e.g., rapamycin). When bound to FK506 or rapamycin, the protein:drug complex further binds and inhibits two important signaling molecules: calcineurin, a key enzyme in T cell activation, and the metabolic enzyme mTOR. The inhibition of these pathways has been functionally linked to immunosuppression (1,2). Through its binding properties, FKBP12 also plays regulatory roles in other pathways. For example, the ryanodine receptor (RyR), a type of Ca2+ release channel, exhibits leakiness in the absence of FKBP12 binding, leading to reduced muscle contractility (3). FKBP12 can also bind TGFBR1 and prevent ligand independent activation (4). The protein also mediates MDM2 degradation by binding and disrupting MDM2/MDM4 association, thereby inducing MDM2 self-ubiquitination and enhancing the sensitivity of cells to chemotherapy induced cellular apoptosis (5).
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.